Skip to content
Axcess News – Lifestyle
Author:
ELI LILLY AND COMPANY
Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting
June 2, 2026
Lilly’s Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
May 31, 2026
Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
May 27, 2026
Lilly announces three acquisitions to build infectious disease portfolio
May 26, 2026
A single dose of Lilly’s PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
May 25, 2026
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
May 7, 2026
ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
April 16, 2026
Foundayo™ (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S.
April 9, 2026
←
Previous Page
1
…
4
5
6